ClinicalTrials.gg
CompletedNCT00922337Updated Mar 6, 2014

The Israeli MGuard Registry

An observational study in Ischemic Heart Disease, Acute Coronary Syndrome and Acute Myocardial Infarction, sponsored by InspireMD. Completed at 2 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-06.

Primary conditionAcute Coronary SyndromeRegistry: Myocardial IschemiaReclassifiedWhy we changed it
Registry
Myocardial Ischemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Acute Coronary Syndrome
Why
  1. The study's listed conditions name Acute Coronary Syndrome, a narrower term within Myocardial Ischemia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by InspireMD · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
86
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 39 studies in Acute Coronary Syndrome with a site in Israel — none open to participants now, 1 under way, none of them phase 3. Acute Coronary Syndrome · Israel.

Enrollment
6th of 11
86 · median 86
Started
2009
with 4 others
Observational
11 of 39
none open now
Registered
13th of 39
by date

Among the 39 studies in Acute Coronary Syndrome with a site in Israel, this one is the 6th largest by enrollment of the 11 observational ones that give a count, is one of 5 that started in 2009, is one of 11 observational ones, and was the 13th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

None of the 39 studies in Acute Coronary Syndrome with a site in Israel is open now. The open studies under Acute Coronary Syndrome, anywhere →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies in Acute Coronary Syndrome with a site in Israel as a file.
02

Study summary

the objective of the Israeli MGurad Registry is to evaluate the 'Real World' Clinical Performance of the InspireMD MGuard Coronary Stent System

Read the detailed description

A Prospective, Observational, Multicenter Registry The primary objective of this registry is to document the safety and overall clinical performance of the MGuard Coronary Stent System in a "real world" patient population requiring stent implantation.

The secondary objective is to assess the event rate in patient subgroups with specific clinical indications and/or vessel and/or lesion characteristics.

03

Conditions studied

  • Ischemic Heart Disease
  • Acute Coronary Syndrome
  • Acute Myocardial Infarction

Browse trials for

Keywords

  • distal embolization
  • thrombotic lesions
  • AMI
  • ACS
  • SVG
04

In context

Acute Coronary Syndrome Reclassified

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

This study's enrollment of 86 is below the median of 500 across 590 observational studies indexed under Acute Coronary Syndrome.

Browse Acute Coronary Syndrome studies →

Lead sponsor

InspireMD is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Compared within Acute Coronary Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myocardial Ischemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with an indication for coronary stent implantation according to the Israeli regulatory approval of the MGuard Coronary Stent System. All patients who receive one or more MGuard Coronary Stent System in one or more target lesions should be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is > 18 years of age
  • The patient has consented to participate by signing the "Patient Form"
  • Patient is suitable for implantation of one or more MGuard Stent System in one or more target lesions
  • Target lesion(s) are according to the Indications for Use and Israeli regulatory approval of the MGuard Stent System
  • The patient is willing and able to cooperate with registry procedures and required follow up

Exclusion criteria

Exclusion Criteria:

  • Heavily calcified target lesions
  • Target lesions with side branch bigger then 2.5mm
  • Target lesions which are distal to newly stented lesion (less than 1 month).
  • Women with known pregnancy
  • Current medical condition with a of less than 12 months
  • Patients with medical conditions that preclude the follow-up as defined in the protocol or that otherwise limits study participation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
86 participants (actual)

Groups and cohorts

  • MGuard

    eligible patients implanted with minimum one MGuard stent

    Device: MGuard Coronary Stent system

Interventions

  • DeviceMGuard Coronary Stent system

    MGuard Coronary Stent system implanted within a PCI

    Also known as: MGuard

07

What researchers measure

Primary outcomes

  1. Major Cardiac Adverse Events rate (MACE)

    Time frame: 1 month

Secondary outcomes

  1. Major Cardiac Adverse Events rate (MACE)

    Time frame: 6 months

  2. Lesion success rate

    Time frame: 1 day

  3. Bleeding complications

    Time frame: 6 months

  4. Stent thrombosis rate

    Time frame: 6 months

  5. Any death

    Time frame: 6 months

08

Study locations

2 sites
  • Laniado Hospital
    Natanya, Israel
  • Asaf Harofe Medical Center
    Zrifin, Israel
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Jun 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2009
First posted
Jun 17, 2009
Start
Jul 2009
Primary completionActual
Jun 2013
CompletionActual
Dec 2013
Last update
Mar 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00922337
Lead sponsor
InspireMD
Responsible party
Sponsor
First posted
Jun 17, 2009
Start date
Jul 2009
Primary completion
Jun 2013
Completion
Dec 2013
Last update
Mar 6, 2014

Study contacts

Elad Yaacoby
study director · InspireMD

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion